Epigenetic Activity of Cancer Therapy Drugs Revealed by HeLa TI Cell-Based Assay
Authors:
- Varvara MaksimovaVMVarvara Maksimova
- Valeriia PopovaVPValeriia Popova
- Alyona KholodovaAKAlyona Kholodova
- Julia MakusJMJulia Makus
- Olga UsalkaOUOlga Usalka
- Eugenia LylovaELEugenia Lylova
- Aleksandr KudriashovAKAleksandr Kudriashov
- Gennady BelitskyGBGennady Belitsky
- Marianna YakubovskayaMYMarianna Yakubovskaya
- Kirill KirsanovKKKirill Kirsanov
Open Access
- 23 February 2026
- journal article
- research article
- Published by MDPI AG in Epigenomes
- Vol. 10 (1) , 14
Abstract
Background/Objectives: The aberrant epigenetic landscape of cancer cells has attracted wide attention, motivating the search for new epigenetically active drugs both for anticancer therapy and for overcoming the drug resistance promoted by epigenetic changes. The use of epi-drugs in cancer therapy requires consideration of the influence of applied treatment on epigenetic regulation of gene expression. Therefore, it is reasonable to screen epigenetically active compounds among the drugs widely used in clinical oncology. Methods: We applied the HeLa TI cell-based assay to analyze the epigenetic activity of 40 drugs including 22 chemotherapeutic, 2 immunotherapeutic, 13 targeted, and 3 palliative agents. Reactivation of the epigenetically silenced GFP reporter gene integrated into the genome of HeLa TI cells was assessed using flow cytometry. Results: Statistically significant increases in the proportions of GFP-positive cells were demonstrated for the alkylating agent chlorambucil; the antimetabolites cytarabine, fluorouracil, gemcitabine, and pemetrexed; the platinum-based compounds cisplatin, and oxaliplatin; the topoisomerase inhibitor topotecan; and the antimicrotubule agents docetaxel, vincristine, and eribulin. Epigenetic activity was also detected for the targeted-therapy agents AZD8055, wortmannin, and cetuximab, as well as for the corticosteroid dexamethasone. Thus, epigenetic activity was revealed for 15 drugs widely used in cancer therapy, which possess different modes of action. Conclusions: Our findings show that many anticancer therapy agents modulate the epigenetic landscape of cancer cells, providing a rationale for expanding their therapeutic applications and enhancing the efficacy of combination strategies by overcoming epigenetically driven chemoresistance.Keywords
Funding Information
- Russian Scientific Foundation (25-15-00432)
This publication has 76 references indexed in Scilit:
- Glucocorticoid Therapy in Acute Lymphoblastic Leukemia: Navigating Short-Term and Long-Term Effects and Optimal Regimen SelectionCurrent Hematologic Malignancy Reports, 2024
- Epigenetic regulation in cancerMedcomm, 2024
- Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of ActionJAMA Network Open, 2021
- Oxaliplatin‐induced neuropathic pain involves HOXA6 via a TET1‐dependent demethylation of the SOX10 promoterInternational Journal of Cancer, 2020
- Tazemetostat: First ApprovalDrugs, 2020
- Wortmannin targeting phosphatidylinositol 3‐kinase suppresses angiogenic factors in shear‐stressed endothelial cellsJournal of Cellular Physiology, 2019
- Structure‐Based Screening of Tetrazolylhydrazide Inhibitors versus KDM4 Histone DemethylasesChemMedChem, 2019
- Preparation and Biochemical Analysis of Classical Histone Deacetylases2016
- Replication stress, a source of epigenetic aberrations in cancer?BioEssays, 2010
- The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a reviewCancer Chemotherapy and Pharmacology, 1999